Observational studyFrontiers in endocrinology2026
Deep learning-derived retinal biomarker associated with diabetes-related amputation in type 2 diabetes.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot (DF)-related amputation remains a major cause of morbidity in patients with type 2 diabetes, yet biomarkers associated with amputation risk remain limited. We aimed to assess the independent association between a deep learning (DL)-derived retinal biomarker using coronary artery calcification (Dr. Noon CVD) and DF-related amputation in patients with type 2 diabetes. This retrospective observational study conducted in a university hospital in South Korea included 392 individuals with type 2 diabetes receiving ophthalmic care (79 with DF-related amputation and 313 without). Participants were randomly split into training (70%) and validation (30%) sets. Model performance in relation to DF-related amputation was assessed using area under the receiver operating characteristic curve (AUC), continuous net reclassification index (cNRI), and integrated discrimination improvement (IDI). Prespecified rule-out (sensitivity ≥0.85) and rule-in (specificity ≥0.90) thresholds were also applied. Adding the retinal biomarker to a basic clinical model showed incremental association with DF-related amputation in the validation set (AUC 0.146, 95% CI: 0.046-0.249; cNRI 0.629, 95% CI: 0.184-1.027; IDI 0.062, 95% CI: 0.012-0.110). The full model achieved an AUC of 0.791, and the association remained consistent across sensitivity analyses using DF risk score derived from the external dataset. Under a 27% amputation prevalence (based on the reported prevalence of amputation among patients with diabetic foot), sensitivity was 87.5% with a negative predictive value of 92.6% at the rule-out cutoff; specificity was 90.4% with a positive predictive value of 56.3% at the rule-in cutoff. A DL-derived retinal biomarker shows meaningful association with DF-related amputation beyond conventional diabetes variables.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.